Drug Trial Radar · NCT07284381
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
261
Actual
Start
Dec 15, 2025
Primary completion
Aug 21, 2026
Study completion Aug 21, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dry Eye Disease (DED) refers to a long-term condition that happens when there is not enough lubrication in your eyes. This can happen when your eye cannot make enough tears or if you make poor-quality tears. The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (ABBV-444) with Refresh Optive UD for 90 days in participants with Dry Eye Disease (DED. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). Participants will be placed into 1 of 2 treatment arms. Each group receives different treatment. Adult participants diagnosed with dry eye disease will be enrolled. Around 250 participants will be enrolled in the study at approximately 20 sites across the US In this study, participants first complete a 7-day run-in period using REFRESH PLUS® eye drops. Those eligible are then randomized to receive ABBV-444 eye drops or REFRESH OPTIVE® Unit Dose eye drops. Participants in both arms will receive treatment for a 90-day treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend multiple required study visits during the study at the study site. The effect of the treatment will be checked by medical assessments and questionnaires.
Conditions
- Dry Eye Disease
Interventions
ABBV-444Drug
Topical eye drop
REFRESH OPTIVE UDDrug
Topical eye drop
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Ocular Surface Disease Index (OSDI) ScoreTime frame: Baseline to Day 90
- Number of Participants with Adverse Events (AEs)Time frame: Baseline to Day 90
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Trinity Research Group /ID# 279914
Dothan, Alabama
Arizona Eye Center - West Ray Road /ID# 267993
Chandler, Arizona
Canyon City Eyecare /ID# 267948
Azusa, California
Global Research Management /ID# 267980
Glendale, California
Lakeside Vision Center /ID# 268544
Irvine, California
Eye Research Foundation /ID# 267931
Newport Beach, California
Lee Shettle Eye and Hearing /ID# 268118
Largo, Florida
Clayton Eye Center /ID# 268097
Morrow, Georgia
Coastal Research Associates - Roswell /ID# 279915
Roswell, Georgia
Kannarr Eye Care /ID# 267979
Pittsburg, Kansas
Butchertown Clinical Trials /ID# 267887
Louisville, Kentucky
Moyes Eye Centers /ID# 267944
Kansas City, Missouri
Northern New Jersey Eye Institute /ID# 267974
South Orange, New Jersey
Rochester Ophthalmological Group - Rochester /ID# 268374
Rochester, New York
Core Inc /ID# 267946
Shelby, North Carolina
Scott and Christie and Associates /ID# 268119
Cranberry Township, Pennsylvania
Southern College of Optometry /ID# 267971
Memphis, Tennessee
Total Eye Care - Memphis /ID# 268327
Memphis, Tennessee
Advancing Vision Research - Smyrna - Stonecrest Parkway /ID# 267939
Smyrna, Tennessee
Piedmont Eye Center /ID# 267929
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.